Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

ngLVA degradation kinetics. by Nicole A. Grieshaber (11175417)

“…<p>Cos-7 cell infected with L2-euoprom-ngLVA, treated with 34 μg/ml chloramphenicol (CAM) or vehicle only (1:1000 EtOH in RPMI) at 35 hpi (arrow). …”

Graphs showing the mean maximum temperature increase at the position with the highest mean temperature increase (A) and the mean temperature increase across all probes (B) for each... by Marsel Ganeyev (21453399)

Table1_CLEC16A variants conferred a decreased risk to allergic rhinitis in the Chinese population.DOCX by Yongliang Niu (14245295)

“…</p><p>Methods: We applied Agena MassARRAY technology platform to genotype five single nucleotide polymorphisms (SNPs) located in CLEC16A in 1004 controls and 995 cases. …”

Table1_CLEC16A variants conferred a decreased risk to allergic rhinitis in the Chinese population.DOCX by Yongliang Niu (14245295)

“…</p><p>Methods: We applied Agena MassARRAY technology platform to genotype five single nucleotide polymorphisms (SNPs) located in CLEC16A in 1004 controls and 995 cases. …”

Effects of TGF-β1 on the expression of fibrosis indicators in HBdSMCs and the effects of MEL on the expression of fibrosis indicators in HBdSMCs induced by TGF-β1. by Yang Zhang (30734)

Retinoic acid alleviates decreases of phospho-Akt and phospho-Bad expression caused by MCAO damage. by Ju-Bin Kang (16021324)

“…Molecular weight (kDa) are depicted at right. Data (<i>n</i> = 5) are represented as mean ± S.E.M. *<i>p</i> < 0.001, **<i>p</i> < 0.01 vs. vehicle + sham animals, #<i>p</i> < 0.01 vs. vehicle + MCAO animals.…”

<i>Ubr5</i>^<i>mt</i> synovium exhibits markers of increased canonical and decreased non-canonical HH signalling. by David Mellis (2833469)

Silencing of RCC1L isoforms alter the levels of mitochondrial ribosomal proteins and biogenesis factors resulting in decreased mitochondrial translation. by Aurelio Reyes (412135)

Descriptives of the study sample, N = 451. by Orrin D. Ware (14829115)

DGAT-1 Inhibitor A922500 decreases the pro-inflammatory profile and cell death induced by SARS-CoV-2 infection and reduces the viral load in human monocyte. by Suelen Silva Gomes Dias (9928813)

Development of a CRISPR/Cas-Based Detection Platform for Tracking Decreased Susceptibility to Cephalosporins in Neisseria gonorrheae by Ziyuan Zhao (2889005)

<i>Kpna1</i> KO mice show decreased anxiety-like behavior in the elevated plus maze. by Koki Sakurai (11690201)